Ulocuplumab

Ulocuplumab

Monoclonal antibody
Type	Whole antibody
Source	Human
Target	C-X-C chemokine receptor type 4
Clinical data
Other names	MDX-1338
ATC code	none
Identifiers
CAS Number	1375830-34-4^Y
ChemSpider	none
UNII	7KNP87L4X4
Chemical and physical data
Formula	C6486H9960N1720O2046S46
Molar mass	146243.78 g·mol^−1

Ulocuplumab (INN;[1] development code MDX-1338) is a monoclonal antibody designed for the treatment of hematologic malignancies.[2]

This drug was developed by Bristol-Myers Squibb.

References

1. World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 110" (PDF). WHO Drug Information. 27 (4).
2. Statement On A Nonproprietary Name Adopted By The USAN Council - Ulocuplumab, American Medical Association.